MAPT and Alzheimer disease: The five major biomarkers and supporting diagnostic modalities of AD (namely CSF Aβ42, amyloid PET, CSF p‐tau, structural MRI, and fluorodeoxyglucose–positron emission tomography [FDG‐PET]) denoted in the staging progression model of AD biomarkers reflect pathophysiological processes and temporal associations between the presence of underlying AD biomarker changes and the onset of clinical symptoms.77